Wegovy’s First Week: What Patients Should Know Before Starting
Wegovy works by affecting the brain to reduce appetite, which leads to lower calorie intake and weight loss. In clinical studies, patients began showing statistically significant weight loss after four weeks of treatment. The most substantial reductions occurred by week 60, with higher doses producing greater results. For example, those on a 2.4-mg weekly dose lost around 9.6% of their body weight by 28 weeks, compared to 7% for those on a 1-mg dose.
Wegovy’s expanded approval offers a new treatment option for adults with MASH and liver fibrosis. The drug’s effectiveness in weight reduction and potential cardiovascular benefits may also support broader health improvements. Patients considering the medication should consult specialists to determine suitability and manage possible side effects.
